폐경 후 질 위축 치료 시장 보고서(2025년)

Postmenopausal vaginal atrophy treatment includes both medical and therapeutic methods aimed at relieving symptoms like vaginal dryness, irritation, and discomfort caused by decreased estrogen levels following menopause. The primary objective is to restore vaginal tissue health, increase moisture and elasticity, and support improved sexual and urinary function. These treatments play a crucial role in preventing complications and greatly enhancing overall quality of life.

The primary categories of postmenopausal vaginal atrophy treatments consist of estrogen-based drugs, non-estrogen-based drugs, and other alternatives. Estrogen-based therapies serve as hormone treatments for addressing menopausal symptoms, promoting reproductive wellness, treating hormone-responsive cancers, and supporting gender-affirming care. These drugs can be administered through various methods, including oral, intravaginal, and others, and are available via multiple distribution channels such as hospital pharmacies, online platforms, and retail pharmacies. The treatments are used in diverse fields including gynecology, sexual wellness, and general pharmaceuticals, and cater to various end-users such as hospitals, home care setups, specialty clinics, and more.

The postmenopausal vaginal atrophy treatment market research report is one of a series of new publications from The Business Research Company that provides detailed insights into market statistics, including the global size of the postmenopausal vaginal atrophy treatment industry, regional market shares, competitive landscape, detailed market segmentation, current trends, growth opportunities, and any additional data needed to succeed in the industry. This report offers a comprehensive overview and an in-depth evaluation of both present conditions and future prospects within the market.

The postmenopausal vaginal atrophy treatment market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Growth during the historical period has been influenced by factors such as a rising prevalence of postmenopausal symptoms, heightened awareness of vaginal health and menopause-related issues, an expanding global population of aging women, increased spending on women's healthcare, and a growing shift towards non-hormonal and localized treatment approaches.

The postmenopausal vaginal atrophy treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. Contributing to this future growth are factors such as a rising number of menopause-focused clinics and gynecological consultations, increasing preference for personalized and patient-specific therapies, enhanced backing from governmental and health-focused organizations, a growing occurrence of early menopause driven by lifestyle and medical interventions, and wider accessibility of over-the-counter and online pharmacy solutions. Prominent market trends projected for the forecast period include innovations in selective estrogen receptor modulators (SERMs), the use of digital health tools and telehealth services, new advancements in drug delivery technologies, progress in non-hormonal treatment strategies, and improvements in minimally invasive gynecological procedures.

The increasing postmenopausal population is expected to drive the growth of the postmenopausal vaginal atrophy treatment market in the coming years. This population includes women who have not had a menstrual period for 12 consecutive months, marking the end of their reproductive phase. As life expectancy rises, more women are living longer and spending additional years in the postmenopausal stage. Treatments for postmenopausal vaginal atrophy help relieve symptoms such as dryness and irritation caused by decreased estrogen levels, thereby promoting vaginal health and improving overall comfort and well-being. For example, according to the Mayo Clinic in October 2022, the number of menopausal and postmenopausal women worldwide is projected to reach 1.2 billion by 2030, with an estimated 47 million women entering this stage each year. This growing demographic is contributing significantly to the expansion of the market.

Companies operating in the postmenopausal vaginal atrophy treatment market are focusing on innovative solutions like estradiol vaginal inserts to deliver targeted symptom relief and enhance adherence to hormone therapy. These inserts are small devices placed in the vagina that release estrogen locally, aiding in the restoration of thinning vaginal tissues due to menopause. They provide effective relief from symptoms such as dryness, itching, and discomfort with minimal systemic absorption. For instance, in January 2024, Knight Therapeutics, a pharmaceutical company based in Canada, launched IMVEXXY in the Canadian market. This product is used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy associated with menopause. It delivers 4 mcg or 10 mcg of estradiol directly to vaginal tissues, supporting mucosal health and reducing pain during intercourse. IMVEXXY's unique softgel formulation ensures fast dissolution and minimal absorption into the bloodstream, offering a convenient, applicator-free, and mess-free alternative to traditional estrogen treatments. This innovation highlights the industry's dedication to developing patient-focused therapies that meet the specific needs of postmenopausal women.

In June 2023, Cosette Pharmaceuticals, a US-based pharmaceutical firm, acquired Intrarosa from Endoceutics Inc. for an undisclosed amount. This acquisition aims to enhance Cosette's women's health portfolio by incorporating a differentiated, patent-protected, commercially available product for the treatment of moderate-to-severe dyspareunia due to menopause. The move reinforces Cosette's commitment to women's health and expands its global reach, utilizing its commercial and manufacturing expertise to maintain patient access to Intrarosa. Endoceutics Inc. is a US-based provider of treatments for postmenopausal vaginal atrophy.

Major players in the postmenopausal vaginal atrophy treatment market are Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Novo Nordisk A/S, Viatris Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Mayne Pharma, Upsher-Smith Laboratories, Alvogen, Ligand Pharmaceuticals Incorporated, Dare Bioscience, Millicent Pharma Limited, TherapeuticsMD, and Bionovo Inc.

North America was the largest region in the postmenopausal vaginal atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in postmenopausal vaginal atrophy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postmenopausal vaginal atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The postmenopausal vaginal atrophy treatment market consists of revenues earned by entities by providing services such as medical consultation and diagnosis, hormonal therapy administration, patient education and counseling, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal vaginal atrophy treatment market also includes sales of vaginal gels, creams, tablets, patches, and rings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postmenopausal Vaginal Atrophy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postmenopausal vaginal atrophy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for postmenopausal vaginal atrophy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postmenopausal vaginal atrophy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Estrogen Based Drugs; Non-Estrogen Based Drugs; Other Therapy Types
• 2) By Route Of Administration: Oral; Intravaginal; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By Application: Gynecology; Sexual Health; Pharmaceuticals
• 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Estrogen Based Drugs: Oral Estrogen Therapy; Transdermal Estrogen Therapy; Estrogen Implants; Vaginal Estrogen Therapy; Branded Products
• 2) By Non-Estrogen Based Drugs: Selective Estrogen Receptor Modulators; Prasterone; Other Non-Estrogen Hormonal Agents
• 3) By Other Therapy Types: Non-Drug Therapies; Over-The-Counter Products
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Postmenopausal Vaginal Atrophy Treatment Market Characteristics

3. Postmenopausal Vaginal Atrophy Treatment Market Trends And Strategies

4. Postmenopausal Vaginal Atrophy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postmenopausal Vaginal Atrophy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Postmenopausal Vaginal Atrophy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Postmenopausal Vaginal Atrophy Treatment Market Growth Rate Analysis
• 5.4. Global Postmenopausal Vaginal Atrophy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Postmenopausal Vaginal Atrophy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Postmenopausal Vaginal Atrophy Treatment Total Addressable Market (TAM)

6. Postmenopausal Vaginal Atrophy Treatment Market Segmentation

• 6.1. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Based Drugs
• Non-Estrogen Based Drugs
• Other Therapy Types
• 6.2. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravaginal
• Other Routes Of Administration
• 6.3. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology
• Sexual Health
• Pharmaceuticals
• 6.5. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Estrogen Based Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Estrogen Therapy
• Transdermal Estrogen Therapy
• Estrogen Implants
• Vaginal Estrogen Therapy
• Branded Products
• 6.7. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Non-Estrogen Based Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators
• Prasterone
• Other Non-Estrogen Hormonal Agents
• 6.8. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Drug Therapies
• Over-The-Counter Products

7. Postmenopausal Vaginal Atrophy Treatment Market Regional And Country Analysis

• 7.1. Global Postmenopausal Vaginal Atrophy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Postmenopausal Vaginal Atrophy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market

• 8.1. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Postmenopausal Vaginal Atrophy Treatment Market

• 9.1. China Postmenopausal Vaginal Atrophy Treatment Market Overview
• 9.2. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Postmenopausal Vaginal Atrophy Treatment Market

• 10.1. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Postmenopausal Vaginal Atrophy Treatment Market

• 11.1. Japan Postmenopausal Vaginal Atrophy Treatment Market Overview
• 11.2. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Postmenopausal Vaginal Atrophy Treatment Market

• 12.1. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Postmenopausal Vaginal Atrophy Treatment Market

• 13.1. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Postmenopausal Vaginal Atrophy Treatment Market

• 14.1. South Korea Postmenopausal Vaginal Atrophy Treatment Market Overview
• 14.2. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Postmenopausal Vaginal Atrophy Treatment Market

• 15.1. Western Europe Postmenopausal Vaginal Atrophy Treatment Market Overview
• 15.2. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Postmenopausal Vaginal Atrophy Treatment Market

• 16.1. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Postmenopausal Vaginal Atrophy Treatment Market

• 17.1. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Postmenopausal Vaginal Atrophy Treatment Market

• 18.1. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Postmenopausal Vaginal Atrophy Treatment Market

• 19.1. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Postmenopausal Vaginal Atrophy Treatment Market

• 20.1. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market

• 21.1. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market Overview
• 21.2. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Postmenopausal Vaginal Atrophy Treatment Market

• 22.1. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Postmenopausal Vaginal Atrophy Treatment Market

• 23.1. North America Postmenopausal Vaginal Atrophy Treatment Market Overview
• 23.2. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Postmenopausal Vaginal Atrophy Treatment Market

• 24.1. USA Postmenopausal Vaginal Atrophy Treatment Market Overview
• 24.2. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Postmenopausal Vaginal Atrophy Treatment Market

• 25.1. Canada Postmenopausal Vaginal Atrophy Treatment Market Overview
• 25.2. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Postmenopausal Vaginal Atrophy Treatment Market

• 26.1. South America Postmenopausal Vaginal Atrophy Treatment Market Overview
• 26.2. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Postmenopausal Vaginal Atrophy Treatment Market

• 27.1. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Postmenopausal Vaginal Atrophy Treatment Market

• 28.1. Middle East Postmenopausal Vaginal Atrophy Treatment Market Overview
• 28.2. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Postmenopausal Vaginal Atrophy Treatment Market

• 29.1. Africa Postmenopausal Vaginal Atrophy Treatment Market Overview
• 29.2. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Postmenopausal Vaginal Atrophy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Postmenopausal Vaginal Atrophy Treatment Market Competitive Landscape
• 30.2. Postmenopausal Vaginal Atrophy Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Postmenopausal Vaginal Atrophy Treatment Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Perrigo Company
• 31.4. Shionogi & Co. Ltd.
• 31.5. Hikma Pharmaceuticals
• 31.6. Amneal Pharmaceuticals LLC
• 31.7. Lupin Pharmaceuticals
• 31.8. Mayne Pharma
• 31.9. Upsher-Smith Laboratories
• 31.10. Alvogen
• 31.11. Ligand Pharmaceuticals Incorporated
• 31.12. Dare Bioscience
• 31.13. Millicent Pharma Limited
• 31.14. TherapeuticsMD
• 31.15. Bionovo Inc.

32. Global Postmenopausal Vaginal Atrophy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postmenopausal Vaginal Atrophy Treatment Market

34. Recent Developments In The Postmenopausal Vaginal Atrophy Treatment Market

35. Postmenopausal Vaginal Atrophy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer